Preclinical Evaluation of Atorvastatin-Loaded PEGylated Liposomes in a Mouse Model of Traumatic Brain Injury
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262412176 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Eun-Sol Hwang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Chonnam National University Medical School and Hospital, Gwangju 61469, Republic of Korea. Hauptthemen laut MEDLINE: Atorvastatin, Liposomes, Brain Injuries, Traumatic, Polyethylene Glycols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation (NRF) of Korea.
Abstract (Originalsprache)
Evidence on the therapeutic use of nanoparticles for traumatic brain injury (TBI) remains limited. This study aimed to evaluate the neuroprotective potential of atorvastatin-loaded polyethylene glycol (PEG)-conjugated liposomes (LipoStatin) in a mouse model of repetitive TBI. TBI was induced using five controlled head impacts with a 120 g weight at 12-h intervals. Mice were randomly assigned to Sham, Control (saline-treated), Statin (free atorvastatin), Liposome (empty PEGylated liposomes without atorvastatin), and LipoStatin (atorvastatin-loaded PEGylated liposome) groups. LipoStatin (10 mg/kg/day) was intravenously administered for 5 days post-injury. Neurological function was evaluated using the neurological severity score (NSS), while blood–brain barrier (BBB) integrity and neuroinflammation were assessed on day 5, and cellular apoptosis on day 12. LipoStatin-treated mice exhibited the lowest NSSs. IVIS® imaging indicated significantly attenuated BBB disruption (p < 0.001), and Western blot analysis revealed restored caveolin-1 protein levels (p < 0.01), which are associated with BBB integrity. TNF-α levels were reduced considerably in the LipoStatin group compared to both the Control (p < 0.001) and Statin (p < 0.05) groups. Immunofluorescence showed reduced co-localization of caspase-3 with PDGFR-β and GFAP, indicating decreased pericyte and astrocyte apoptosis. These findings suggest that LipoStatin may confer neuroprotection in TBI by stabilizing BBB integrity, reducing inflammation, and mitigating cell death, supporting its potential as an improved nanocarrier-based therapeutic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Chonnam National University Medical School and Hospital, Gwangju 61469, Republic of Korea.
- Department of Nuclear Medicine, Chonnam National University Medical School and Hospital, Gwangju 61469, Republic of Korea.
- Department of Neurology, Chonnam National University Medical School and Hospital, Gwangju 61469, Republic of Korea.
- Department of Radiology, Chonnam National University Medical School and Hwasun Hospital, Hwasun 58128, Republic of Korea.
ORCID-Profile: Ja-Hae Kim, Raveena Nagareddy, Yong-Yeon Jeong, Kang-Ho Choi
Förderung
- National Research Foundation (NRF) of Korea
Zitieren
APA
Hwang, E. S., Kim, J. H., Kim, J. H., Nagareddy, R., Jeong, Y. Y., & Choi, K. H. (2025). Preclinical Evaluation of Atorvastatin-Loaded PEGylated Liposomes in a Mouse Model of Traumatic Brain Injury. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262412176
Vancouver
Hwang ES, Kim JH, Kim JH, Nagareddy R, Jeong YY, Choi KH. Preclinical Evaluation of Atorvastatin-Loaded PEGylated Liposomes in a Mouse Model of Traumatic Brain Injury. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262412176
BibTeX
@article{Hwang2025,
author = {Hwang, Eun-Sol and Kim, Ja-Hae and Kim, Ji-Hye and Nagareddy, Raveena and Jeong, Yong-Yeon and Choi, Kang-Ho},
title = {Preclinical Evaluation of Atorvastatin-Loaded PEGylated Liposomes in a Mouse Model of Traumatic Brain Injury},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262412176}
}
EUVIMED